Brad A. Bryan
Center of Excellence in Cancer Research, Paul Foster School of Medicine
Texas Tech University, USA
Dr. Bryan received his B.S. in Biological Sciences with a minor in Chemistry from Stephen F. Austin State University (Nacogdoches, Texas) in 1999, M.S. in Biochemistry from Texas A&M University (College Station, Texas) in 2003, and Ph.D. in Biomedical Sciences from Texas A&M Health Sciences Center in 2005. He performed his postdoctoral research in the lab of Dr. Patricia D’Amore at Harvard Medical School in the Schepen’s Eye Research Institute (Boston, MA) from 2005 to 2008. He was recruited to Worcester State University (Worcester, MA) as an assistant professor of Biology from 2008-2011 where he taught undergraduate and graduate biology and biotechnology courses and was awarded the university’s first grant from the National Institutes of Health. In 2011 Dr. Bryan moved his lab to Texas Tech University Health Sciences Center in El Paso Texas where he is currently an assistant professor in the Department of Biomedical Sciences at the Paul L. Foster School of Medicine. Dr. Bryan’s laboratory has been awarded grants from the National Institutes of Health, Liddy Shriver Sarcoma Initiative, I. Aisiku, and multiple seed grants. Dr. Bryan is a member of the North American Vascular Biology Association, the American Society for Cell Biology, and the American Association of Cancer Researchers and has presented his work at numerous national and international venues. He has served as a scientific textbook and manuscript reviewer for multiple prestigious publishing companies, a grant editor for the National Institutes of Health and the Scientific Committee of the Association Francaise contre les Myopathies, and as a consultant for several pre-clinical drug development studies in private industry.
The research in the Bryan lab is focused on the subcellular mechanics and cellular signaling involved in the formation of the cardiovascular system. We are particularly interested in how these pathways are deregulated in aberrant vascular states such as hemangiomas, vascular malformations, and cancer. Insights gained from this work can lead to a better understanding of the cause and treatment of vascular disease and cancer. To achieve these goals, we are developing novel experimental techniques to (1) elucidate the mechanisms by which cell shape and mechanical stress affect gene expression, (2) identify the genetic and epigenetic components controlling hemangioma and vascular malformation progression, and (3) develop advanced therapeutics against a variety of vascular tumors including hemangioendotheliomas and angiosarcomas.